WILMINGTON, Mass., Sept. 2, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
announced today it has sold $1.2
million worth of trace detectors to a customer in the
European Union. The units will be deployed for critical
infrastructure protection and homeland security.
"We won this contract in a highly competitive environment. The
contract win was a result of our trace detectors exceeding the
customer's expectations, particularly when compared to competitive
products, as well as the service and support provided by our
superior local distributor," stated Dr. Darryl Jones, Implant Sciences' Vice President
of Global Sales and Marketing.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013
Homeland Security Award for "Best Explosives Detection
Solution". All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
we will be required to repay all of our indebtedness to our secured
lenders by March 31, 2015; if we are
unable to satisfy our obligations and to raise additional capital
to fund operations, our secured lenders may seize our assets and
our business may fail; we continue to incur substantial operating
losses and may never be profitable; our independent registered
public accounting firm has expressed substantial doubt as to our
ability to continue as a going concern; our explosives detection
products and technologies (including any new products we may
develop) may not be accepted by the Transportation Security
Administration or by other U.S. or foreign government and law
enforcement agencies or commercial consumers of security products;
economic, political and other risks associated with international
sales and operations could adversely affect our sales; liability
claims related to our products or our handling of hazardous
materials could damage our reputation and have a material adverse
effect on our financial results; our business is subject to intense
competition; our markets are subject to rapid technology change and
our success will depend on our ability to develop and introduce new
products; we may not be able to retain our management and key
employees or identify, hire and retain additional personnel as
needed; we may not be able to enforce our patent and other
intellectual property rights or operate without infringing on the
proprietary rights of others; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and 8-K.
Such statements are based on management's current expectations and
assumptions which could differ materially from the forward-looking
statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation